Safety Concerns
Secondary malignancy risk from uncontrolled integration.
Integration near oncogenic sites presents significant and unresolved therapeutic barriers — particularly for CAR-T and HSC-targeted therapies.
Vector Design Solutions // 01
Overcoming the limits of conventional viral vectors through precision-controlled engineering — for next-generation gene therapies built on safety, efficiency, and scale.
5×
More efficient than
conventional vectors
2×
Platforms: LentiNext®
& RetroNext®
4.7+kb
Potential payloads beyond
conventional AAV limits
ENV / CAPSID
INTEGRATION CTRL
PROMOTER
ACCESSORY ELEM.
The Problem // 02
Three long-standing barriers keep gene therapies stuck in a compromise between safety, cost, and capability.
Secondary malignancy risk from uncontrolled integration.
Integration near oncogenic sites presents significant and unresolved therapeutic barriers — particularly for CAR-T and HSC-targeted therapies.
Low transduction drives unsustainable COGS.
Low transduction efficiency and elevated viral dose requirements push manufacturing costs beyond sustainable production thresholds.
4.7 kb AAV payload caps therapeutic scope.
Limited payload and reduced efficiency in hard-to-transduce cells (NK, HSC, primary T) constrain what gene therapies can address.
The Solution // 03
Match the vector to the therapeutic need — transient delivery, safe integration, or high-efficiency transduction — all built on our LentiNext® and RetroNext® platforms.
Non-Integrating
NITransient gene expression without permanent integration.
Safe Integration
SISustained expression with therapeutic risk reduction.
High Efficiency
HEMultifold efficiency gains with scalable production.
Modular by design. Components — envelopes, promoters, accessory elements — can be combined across classes to match your therapeutic profile. Discuss a custom configuration →
One-Stop Vector Engineering // 04
Every vector moves through precision engineering, molecular validation, pilot production, and potency QC before hand-off.
Component optimization based on target specifications and therapeutic objectives.
Molecular validation and plasmid construction with rigorous QC checkpoints.
Pilot-scale viral vector production with scalable, reproducible manufacturing protocols.
Functional QC and vector potency verification for regulatory-grade assurance.
Applications // 05
Engineered across the gene therapy landscape — from CAR-T safety to large-payload delivery beyond AAV limits.
Oncogenic site-avoiding LentiNext® / RetroNext® SI vectors with precision-engineered integration control — aligned with current FDA safety considerations.
Strategically combined envelopes, promoters, and accessory elements optimized for NK cells, HSCs, and primary T cells — where conventional vectors underperform.
LentiNext® / RetroNext® NI vectors enable flexible, re-dosable treatment strategies without permanent genomic integration — ideal for CRISPR and related editing platforms.
Delivery of large genetic payloads including complex multi-gene circuits, overcoming the conventional AAV packaging constraint for next-generation therapeutics.
Collaboration Models // 07
Three engagement paths, calibrated to your program stage — from fee-for-service to joint IP development and platform licensing.
Custom Solutions
End-to-end vector engineering
Leverage our proprietary, customized vector solutions to precisely align with your therapeutic objectives and clinical development timeline.
Start a projectCo-Development
Collaborative development
Collaborative development of indication-specific therapies, combining your clinical insight with our vector engineering expertise.
Explore collaborationPlatform Licensing
Proprietary platform licensing
Access to proprietary LentiNext® and RetroNext® technologies for integration into your partner development and manufacturing pipelines.
Request termsGet in Touch // 08
Our specialists will respond within two business days to discuss your specific therapeutic needs and the best path forward.